Evidence map›Paper›PMID 39969690›Full record

ArticleClinical autonomic research : official journal of the Clinical Autonomic Research Society2025

Heartbeat signature for predicting motor and non-motor involvement among nonparkinsonian LRRK2 G2019S mutation carriers.

Claudia Carricarte Naranjo, Connie Marras, Naomi P Visanji, David J Cornforth, Lazaro Sanchez-Rodriguez, Birgitt Schüle, Samuel M Goldman, Mario Estévez, Phyllis K Stein, Herbert F Jelinek and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical autonomic research : official journal of the Clinical Autonomic Research Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Claudia Carricarte NaranjoFacultad de Biología, Universidad de La Habana, La Habana, Cuba. carri@fbio.uh.cu.ORCID http://orcid.org/0000-0001-8764-3583
Connie MarrasEdmond J Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, Toronto, ON, Canada.
Naomi P VisanjiEdmond J Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, Toronto, ON, Canada.
David J CornforthMember of the National Coalition of Independent Scholars (NCIS), Brattleboro, VT, USA.
Lazaro Sanchez-RodriguezDepartment of Radiology, University of Calgary, Calgary, AB, Canada.
Birgitt SchüleDepartment of Pathology, Stanford School of Medicine, Stanford, CA, USA.
Samuel M GoldmanDepartment of Neurology, University of California, San Francisco, CA, USA.
Mario EstévezDepartamento de Neurofisiología Clínica, Instituto de Neurología y Neurocirugía, La Habana, Cuba.
Phyllis K SteinSchool of Medicine, Washington University, St. Louis, MO, USA.
Herbert F JelinekDepartment of Medical Sciences and Biotechnology Center, Khalifa University, Abu Dhabi, UAE.
Anthony E LangEdmond J Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, Toronto, ON, Canada.
Andrés MachadoFacultad de Biología, Universidad de La Habana, La Habana, Cuba.

Funding

Michael J. Fox Foundation for Parkinson's Research 6896
6 · The paper itself

Abstract

purposeIncreased beat-to-beat heart rate variability (HRV) is a feature of patients with Parkinson's disease (PD) who carry the G2019S mutation in the LRRK2 gene (LRRK2-PD). Since LRRK2 mutations have incomplete penetrance, HRV changes preceding PD conversion would likely be observed only in a subset of LRRK2 non-manifesting carriers (NMC). We aimed to assess HRV in a subgroup of NMC with distinctive characteristics of LRRK2-PD, identified through clustering analysis.

methodsHRV measures derived from 300 normal heartbeat intervals extracted from the electrocardiograms of 25 NMC, 32 related non-carriers (RNC), 27 unrelated healthy controls, and 14 patients with LRRK2-PD were analyzed. Clinical symptoms were evaluated using questionnaires and scales, and three NMC subgroups were identified using a k-means cluster analysis on the basis of the deceleration capacity of heart rate (DC) and Rényi entropy. Standard and advanced HRV measures were compared using multiple regression analysis, controlling for age, sex, and mean heart rate.

resultsBeat-to-beat HRV markers were significantly increased in a subgroup of seven NMC (NMC2, 28%) compared with RNC and controls. Increased irregularity and DC were also verified in the NMC2 compared with controls, and were typical traits in both the NMC2 and RNC. Overall, the HRV profile of NMC2 was comparable to that of patients with LRRK2-PD. NMC2 further exhibited greater motor and non-motor traits than the other NMC, RNC, and controls.

conclusionsOur results confirmed that HRV characteristics of LRRK2-PD are also found in a subset of NMC displaying clinical traits of LRRK2-PD. Further research is needed to clarify whether higher HRV represents a LRRK2-PD prodromal manifestation.

Indexed as

Heart RateLeucine-Rich Repeat Serine-Threonine Protein Kinase-2MutationParkinson DiseaseAdultAgedElectrocardiographyFemaleHeterozygoteHumansMaleMiddle AgedLeucine-Rich Repeat Serine-Threonine Protein Kinase-2LRRK2 protein, humanCardiac autonomic modulationDeceleration capacity of heart rateHeart rate variabilityLRRK2 mutationParkinson’s diseaseRényi entropy

Identifiers

PMID39969690

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.